[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K: SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia; 2007 Jan;9(1):23-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk.
  • The interplay between peritoneal mesothelial cells and ovarian cancer cells is critical for the initiation and peritoneal dissemination of, and ascites formation in, ovarian cancer.
  • The production of lysophosphatidic acid (LPA) by both peritoneal mesothelial cells and ovarian cancer cells has been shown to promote metastatic phenotype in ovarian cancer.
  • Our results strongly suggest that SPARC exerts a dual inhibitory effect on LPA-induced mesothelial-ovarian cancer cell crosstalk through the regulation of both LPA-induced IL-6 production and function.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1994 Apr 1;73(7):1882-8 [8137215.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4209-17 [15205333.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Cytokine. 1995 Aug;7(6):542-7 [8580370.001]
  • [Cites] Oncogene. 1996 May 2;12(9):1895-901 [8649850.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1A):337-42 [9066674.001]
  • [Cites] Cancer Treat Rev. 1997 Mar;23(2):113-31 [9225962.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2212-21 [9278309.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1307-13 [9816301.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):364-8 [9887232.001]
  • [Cites] ANZ J Surg. 2004 Nov;74(11):997-1002 [15550091.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):45-52 [15471896.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10564-71 [15653692.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4673-82 [15930285.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jul;289(1):C2-11 [15728708.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):305-13 [15954082.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(21):9700-12 [16227616.001]
  • [Cites] Am J Pathol. 2005 Dec;167(6):1739-52 [16314484.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10794-800 [16322225.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] Endocrinology. 2006 Oct;147(10):4883-92 [16809448.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] J Soc Gynecol Investig. 2001 Jan-Feb;8(1):1-13 [11223350.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] J Clin Invest. 2001 May;107(9):1049-54 [11342565.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):609-22 [11485919.001]
  • [Cites] J Lipid Res. 2002 Mar;43(3):463-76 [11893783.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):617-29 [11959895.001]
  • [Cites] Biochim Biophys Acta. 2002 Nov 11;1592(3):323-43 [12421676.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jun 6;305(3):462-9 [12763015.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1570-2 [12824286.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21154-9 [15024019.001]
  • [Cites] Cancer. 1995 Feb 15;75(4):1004-9 [7842401.001]
  • (PMID = 17325741.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K01 CA089689; United States / NHLBI NIH HHS / HL / R01 HL074279; United States / NHLBI NIH HHS / HL / HL074279; United States / NCI NIH HHS / CA / K01-CA089689
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Lysophospholipids; 0 / Osteonectin; 0 / RNA, Messenger; 0 / Receptors, Lysophosphatidic Acid; 22002-87-5 / lysophosphatidic acid; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ PMC1803033
  •  go-up   go-down


2. Tabata C, Tabata R, Hirayama N, Yasumitsu A, Yamada S, Murakami A, Iida S, Tamura K, Terada T, Kuribayashi K, Fukuoka K, Nakano T: All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice. Eur Respir J; 2009 Nov;34(5):1159-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice.
  • Malignant pleural mesothelioma (MPM) is an aggressive malignant tumour of mesothelial origin associated with asbestos exposure.
  • We estimated the tumour growth and performed quantitative measurements of IL-6, TGF-beta1 and platelet-derived growth factor (PDGF) receptor (PDGFR)-beta mRNA levels both of cultured MPM cells and cells grown in mice with or without the administration of ATRA.
  • ATRA significantly inhibited MPM tumour growth.
  • [MeSH-major] Mesothelioma / drug therapy. Pleural Neoplasms / drug therapy. Tretinoin / pharmacology
  • [MeSH-minor] Animals. Asbestos. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Interleukin-6 / metabolism. Mice. Mice, SCID. Neoplasm Transplantation. Platelet-Derived Growth Factor / metabolism. Proto-Oncogene Proteins c-sis. RNA, Messenger / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism. Transforming Growth Factor beta1 / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443527.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1; 0 / platelet-derived growth factor BB; 1332-21-4 / Asbestos; 5688UTC01R / Tretinoin; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  •  go-up   go-down


3. Kalyani R, Das S: Adenomatatoid tumor: Cytological diagnosis of two cases. J Cytol; 2009 Jan;26(1):30-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatatoid tumor: Cytological diagnosis of two cases.
  • Adenomatoid tumor is a benign neoplasm of mesothelial cell origin that occurs in both male and female genital tracts.
  • Fine needle aspiration cytology has an important role in the preoperative diagnosis of the male genital adenomatoid tumor and is a rapid, reliable, conclusive, and cost-effective diagnostic tool that can be used to take appropriate surgical decisions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):495-7 [10349389.001]
  • [Cites] BJU Int. 2005 Jul;96(1):67-9 [15963123.001]
  • [Cites] Acta Cytol. 1989 Jan-Feb;33(1):6-10 [2916372.001]
  • [Cites] J Urol. 1995 Nov;154(5):1756-8 [7563340.001]
  • [Cites] Acta Cytol. 1998 Nov-Dec;42(6):1458-60 [9850662.001]
  • [Cites] AJR Am J Roentgenol. 1983 Mar;140(3):511-5 [6600544.001]
  • [Cites] J Urol. 1988 Apr;139(4):819-20 [3352056.001]
  • (PMID = 21938146.001).
  • [ISSN] 0970-9371
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167987
  • [Keywords] NOTNLM ; Adenomatoid tumor / FNAC / epididymis / testis
  •  go-up   go-down


Advertisement
4. Białas M, Szczepański W, Szpor J, Okoń K, Kostecka-Matyja M, Hubalewska-Dydejczyk A, Tomaszewska R: Adenomatoid tumour of the adrenal gland: a case report and literature review. Pol J Pathol; 2010;61(2):97-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumour of the adrenal gland: a case report and literature review.
  • Adenomatoid tumour (AT) is a rare, benign neoplasm of mesothelial origin, which usually occurs in the genital tract of both sexes.
  • The most important thing about these tumours is not to mis-diagnose them as primary malignant or metastatic neoplasms.
  • The tumour was an incidental finding during abdominal CT-scan for an unrelated condition.
  • [MeSH-major] Adenomatoid Tumor / pathology. Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Asymptomatic Diseases. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Incidental Findings. Male. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20924994.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Leaha C, Opris I, Macé P, Resch B, Sabourin JC: [Cystic adenomatoid tumor of the uterus]. Ann Pathol; 2009 Apr;29(2):134-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cystic adenomatoid tumor of the uterus].
  • Adenomatoid tumors are benign neoplasms of mesothelial origin, which involve the feminine and masculine genital tracts.
  • Our study presents an adenomatoid tumour, of cystic shape, which enables discussion of the histogenesis of this tumour and enlightenment of differential diagnoses which can at times result in an incorrect malignant diagnosis.
  • [MeSH-major] Adenomatoid Tumor / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19364588.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


6. Kontos S, Fokitis I, Karakosta A, Koritsiadis G, Mitsios K, Koutsikos S, Koritsiadis S: Adenomatoid tumor of epididymidis: A case report. Cases J; 2008;1(1):206
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of epididymidis: A case report.
  • BACKGROUND: Adenomatoid tumors are regarded as distinctive benign mesothelial neoplasms of the paratesticular region, most commonly occuring at the tail of the epididymidis.Because of its rarity, the clinical and histopathological aspects are discussed.
  • CASE PRESENTATION: We present the case of a 41-year-old patient with an adenomatoid tumour located in the tail of the left epididymis that referred to our department with gradual enlarged intrascrotal mass.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Eur Urol. 1996;30(1):127-8 [8854081.001]
  • [Cites] Urology. 1985 Jun;25(6):653-4 [4012964.001]
  • [Cites] Semin Diagn Pathol. 2000 Nov;17(4):294-306 [11202546.001]
  • [Cites] J Urol. 2005 Aug;174(2):723 [16006963.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):77-83 [14707867.001]
  • [Cites] Histopathology. 2001 May;38(5):479 [11422488.001]
  • [Cites] Pathol Annu. 1990;25 Pt 2:51-108 [2202966.001]
  • [Cites] Urology. 1975 Nov;6(5):635-41 [1189154.001]
  • (PMID = 18831762.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2566564
  •  go-up   go-down


7. Linke R, Klein A, Seimetz D: Catumaxomab: clinical development and future directions. MAbs; 2010 Mar-Apr;2(2):129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the peritoneum is of mesothelial origin and therefore lacks EpCAM expression, the intraperitoneal administration of catumaxomab is an attractive targeted immunotherapeutic approach.
  • Catumaxomab is able to destroy EpCAM positive tumor cells in the peritoneal cavity known as the main cause of malignant ascites.
  • [MeSH-major] Antibodies, Bispecific / pharmacology. Antineoplastic Agents / pharmacology. Carcinoma / drug therapy. Immunotherapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antigens, Neoplasm / immunology. Cell Adhesion Molecules / immunology. Drug Discovery. Epithelial Cell Adhesion Molecule. European Union. Humans. Immunomodulation


8. Wynne P, Newton C, Ledermann JA, Olaitan A, Mould TA, Hartley JA: Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer; 2007 Oct 8;97(7):927-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite high tumour response rates to platinum-based chemotherapy in ovarian cancer survival is poor due to the emergence of drug resistance.
  • A modification of the single cell gel electrophoresis (comet) assay allows the sensitive detection of DNA interstrand crosslinking in both tumour and normal cells derived directly from clinical material.
  • Tumour cells isolated from 50 ovarian cancer patients were treated ex vivo with 100 microM cisplatin for 1 h and crosslink formation and repair (unhooking) measured.
  • No significant difference in the peak level of crosslinking in tumour cells was observed between patients who were either newly diagnosed or previously treated with platinum-based therapy, or between tumour and mesothelial cells from an individual patient.
  • At 24 h in the 36 newly diagnosed patient tumour samples, only one gave >50% repair and 23 gave <10% repair; however, 19 out of 22 treated patient samples gave >10% repair and 14 showed >50% repair.
  • The estimated median difference (newly diagnosed minus treated) was -52 (95% CI -67 to -28), and the P-value from a Mann-Whitney test was <0.001.
  • In eight patients, it was possible to obtain tumour samples prior to any chemotherapy, and also on relapse or at interval debulking surgery following platinum-based chemotherapy.
  • These data demonstrate increased repair of DNA interstrand crosslinks in ovarian tumour cells following platinum therapy which may contribute to clinical acquired resistance.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cisplatin / pharmacology. DNA / genetics. DNA Repair / drug effects. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1979 Feb;39(2 Pt 1):365-9 [570092.001]
  • [Cites] Curr Cancer Drug Targets. 2003 Feb;3(1):21-9 [12570658.001]
  • [Cites] Radiat Res. 1990 Apr;122(1):86-94 [2320728.001]
  • [Cites] J Clin Oncol. 1991 Mar;9(3):389-93 [1999708.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;35(4):323-6 [7828275.001]
  • [Cites] Carcinogenesis. 1995 Oct;16(10):2447-53 [7586150.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1535-42 [9893624.001]
  • [Cites] Clin Cancer Res. 1999 Mar;5(3):507-12 [10100700.001]
  • [Cites] Br J Cancer. 2005 Jun 6;92(11):1997-2003 [15886706.001]
  • [Cites] Oncology. 2005;68(4-6):293-8 [16020955.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6100-2 [16144907.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 8:viii7-viii12 [16239238.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79 [17018256.001]
  • [Cites] Drugs. 2000;59 Suppl 4:1-8; discussion 37-8 [10864225.001]
  • [Cites] Biochem Pharmacol. 2000 Nov 1;60(9):1305-13 [11008124.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1671-6 [11401322.001]
  • [Cites] Lancet Oncol. 2001 Aug;2(8):483-90 [11905724.001]
  • [Cites] Blood. 2002 Jul 1;100(1):224-9 [12070031.001]
  • [Cites] Nucleic Acids Res. 2002 Sep 1;30(17):3848-56 [12202770.001]
  • [Cites] Br J Cancer. 1989 Apr;59(4):650-3 [2713253.001]
  • (PMID = 17848946.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cross-Linking Reagents; 9007-49-2 / DNA; EC 2.7.7.7 / DNA-Directed DNA Polymerase; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2360410
  •  go-up   go-down


9. Mani H, Merino MJ: Mesothelial neoplasms presenting as, and mimicking, ovarian cancer. Int J Gynecol Pathol; 2010 Nov;29(6):523-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelial neoplasms presenting as, and mimicking, ovarian cancer.
  • The involvement of the viscera is usually secondary to bulky and extensive serosal disease.
  • One patient had a borderline mucinous tumor with the mesothelioma occurring as a mural nodule, an association not described earlier.
  • Mesothelial neoplasms can present as ovarian masses in young women.
  • [MeSH-major] Abdominal Neoplasms / pathology. Mesothelioma / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20881862.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


10. Garg K, Lee P, Ro JY, Qu Z, Troncoso P, Ayala AG: Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases. Ann Diagn Pathol; 2005 Feb;9(1):11-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases.
  • Adenomatoid tumors are relatively uncommon benign neoplasms of mesothelial origin, usually occurring in the male and female genital tracts.
  • Because of its glandular pattern, an adenomatoid tumor may be confused with an adenocarcinoma.
  • The tumor was an incidental radiological finding in another case and was discovered during the course of a workup for hypertension in the third case.
  • Immunohistochemical stains for calretinin and cytokeratin 5/6 were positive, confirming the tumors' mesothelial origin.
  • In our experience, the key to the diagnosis of this rare benign tumor is to consider adenomatoid tumor in the differential diagnosis of any glandular tumor occurring in the adrenal gland.
  • [MeSH-major] Adenoma / pathology. Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Biomarkers, Tumor / metabolism. Calbindin 2. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Cysts / complications. Cysts / metabolism. Cysts / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged. S100 Calcium Binding Protein G / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692945.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


11. Wakely PE Jr: Cytopathology of thymic epithelial neoplasms. Semin Diagn Pathol; 2005 Aug;22(3):213-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathology of thymic epithelial neoplasms.
  • In part, this is because the tumor is uncommon and aspirates are infrequently encountered, a technically proficient interventional radiologist is needed, epithelial cells may be difficult to recognize in lymphoid rich aspirate smears, and there is inherent sampling error in a tumor that frequently displays heterogeneous histopathology.
  • WHO Type A thymoma may contain only epithelial cells and thus mimic a spindle cell neoplasm, or mesothelial cell clusters.
  • [MeSH-major] Thymoma / pathology. Thymus Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711402.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


12. Zhong J, Gencay MM, Bubendorf L, Burgess JK, Parson H, Robinson BW, Tamm M, Black JL, Roth M: ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol; 2006 May;207(2):540-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells.
  • Pleural malignant mesothelioma is a locally aggressive tumor of mesothelial cell origin.
  • In other tumor types high expression of matrix metalloproteinase (MMP)-2, together with membrane-type1-MMP (MT1-MMP), and low levels of the tissue inhibitor of MMP (TIMP)-2 have been correlated with aggressive tumor progression and low survival rates.
  • Therefore, we compared the expression and activation of these three factors and their regulation by two mesothelioma associated growth factors, platelet-derived growth factor (PDGF)-BB, and transforming growth factor (TGF)-beta1 in six human mesothelioma and one mesothelial cell line.
  • PDGF-BB was a chemoattractant for mesothelial cells, and its effect was increased in the presence of TGF-beta1.
  • TGF-beta1 stimulated the de novo synthesis of pro-MMP-2 in both cell types.
  • In cell culture and tissue sections only mesothelial cells expressed MT1-MMP.
  • Mesothelioma progression depends on an interaction with mesothelial cells that provide MT1-MMP necessary to activate pro-MMP-2 to facilitate migration through an extracellular matrix (ECM) layer.
  • [MeSH-minor] Cell Line. Cell Line, Tumor. Cell Proliferation / drug effects. Epithelial Cells / chemistry. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Humans. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Matrix Metalloproteinase Inhibitors. Matrix Metalloproteinases, Membrane-Associated. Mesothelioma / chemistry. Mesothelioma / metabolism. Mesothelioma / pathology. Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 1 / genetics. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors. Mitogen-Activated Protein Kinase 3 / genetics. Mitogen-Activated Protein Kinase 3 / metabolism. Platelet-Derived Growth Factor / pharmacology. Protease Inhibitors / pharmacology. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins c-sis. RNA, Small Interfering / genetics. Tissue Inhibitor of Metalloproteinase-2 / genetics. Tissue Inhibitor of Metalloproteinase-2 / metabolism. Transforming Growth Factor beta / pharmacology. Transforming Growth Factor beta1. p38 Mitogen-Activated Protein Kinases / antagonists & inhibitors. p38 Mitogen-Activated Protein Kinases / genetics. p38 Mitogen-Activated Protein Kinases / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447244.001).
  • [ISSN] 0021-9541
  • [Journal-full-title] Journal of cellular physiology
  • [ISO-abbreviation] J. Cell. Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Matrix Metalloproteinase Inhibitors; 0 / Platelet-Derived Growth Factor; 0 / Protease Inhibitors; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-sis; 0 / RNA, Small Interfering; 0 / TGFB1 protein, human; 0 / Tissue Inhibitor of Metalloproteinases; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; 0 / platelet-derived growth factor BB; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases, Membrane-Associated; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


13. van Grevenstein WM, Hofland LJ, van Rossen ME, van Koetsveld PM, Jeekel J, van Eijck CH: Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers. Dig Dis Sci; 2007 Oct;52(10):2775-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers.
  • The aim of this study was to investigate the effects of inflammatory cytokines on the interaction between tumor and mesothelial cells.
  • Tumor cell adhesion to a mesothelial monolayer was assessed after preincubation of the mesothelium with interleukin (IL)-1beta, IL-6, and tumor necrosis factor (TNF)-alpha.
  • Preincubation of the mesothelial monolayer with IL-1beta or TNF-alpha resulted in enhanced tumor cell adhesion of Caco2 and HT29 colon carcinoma cells.
  • Blocking experiments with anti-IL-1beta and anti-TNF-alpha resulted in significant inhibition of the cytokine-stimulated tumor cell adhesion.
  • The presented results prove that IL-1beta and TNF-alpha are significant stimulating factors in tumor cell adhesion in vitro and may therefore account for tumor recurrence to the peritoneum in vivo.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion / physiology. Colonic Neoplasms / metabolism. Interleukin-1beta / pharmacology. Interleukin-6 / pharmacology. Intestinal Mucosa / metabolism. Tumor Necrosis Factor-alpha / pharmacology
  • [MeSH-minor] Caco-2 Cells. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. HT29 Cells. Humans. Immunohistochemistry. Monocytes / metabolism. Monocytes / pathology. Receptors, Cytokine / genetics. Receptors, Cytokine / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394066.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / DNA, Neoplasm; 0 / Interleukin-1beta; 0 / Interleukin-6; 0 / Receptors, Cytokine; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


14. Na D, Lv ZD, Liu FN, Xu Y, Jiang CG, Sun Z, Miao ZF, Li F, Xu HM: Transforming growth factor beta1 produced in autocrine/paracrine manner affects the morphology and function of mesothelial cells and promotes peritoneal carcinomatosis. Int J Mol Med; 2010 Sep;26(3):325-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transforming growth factor beta1 produced in autocrine/paracrine manner affects the morphology and function of mesothelial cells and promotes peritoneal carcinomatosis.
  • Human peritoneal mesothelial cells (HPMCs) in intact mesothelium have been demonstrated to protect against tumor peritoneal metastasis.
  • In this study, we investigated the effects of TGF-beta1 on tumor-mesothelial interaction.
  • HMrSV5 cells, a human peritoneal mesothelial cell line, were co-incubated with TGF-beta1, gastric cancer cells, or gastric cancer cells and TGF-beta1 receptor inhibitor SB431542.
  • Tumor-mesothelial cell adhesion was also examined.
  • Results showed a significant elevation of TGF-beta1 expression, which is companied by dramatically increased phosphorylated-smad 2/3 levels, after mesothelial cell co-culture with the gastric cancer cell line.
  • In addition, mesothelial cells exposed to gastric cancer cells or TGF-beta1 became exfoliated and exhibited signs of injury, while blocking TGF-beta1 can partially inhibit these effects.
  • These results indicate that soluble factors, such as TGF-beta1, produced in autocrine/paracrine manner in the peritoneal cavity, affect the morphology and function of mesothelial cells so that the resulting environment becomes favorable for peritoneal metastases.
  • [MeSH-major] Autocrine Communication / physiology. Carcinoma. Epithelial Cells. Epithelium / metabolism. Paracrine Communication / physiology. Peritoneal Neoplasms. Stomach Neoplasms. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Apoptosis / physiology. Benzamides / metabolism. Cell Adhesion / physiology. Cell Shape. Cells, Cultured. Coculture Techniques. Culture Media, Conditioned. Culture Media, Serum-Free. Dioxoles / metabolism. Humans. Neoplasm Metastasis. Receptors, Transforming Growth Factor beta / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664947.001).
  • [ISSN] 1791-244X
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide; 0 / Benzamides; 0 / Culture Media, Conditioned; 0 / Culture Media, Serum-Free; 0 / Dioxoles; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


15. Jung CK, Choi YJ, Lee KY, Bae JS, Kim HJ, Yoon SK, Son YI, Chung JH, Oh YL: The cytological, clinical, and pathological features of the cribriform-morular variant of papillary thyroid carcinoma and mutation analysis of CTNNB1 and BRAF genes. Thyroid; 2009 Aug;19(8):905-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The goal of this study was to determine the clinicopathological features of CMVPTC and whether the tumor can be diagnosed by fine-needle aspiration cytology.
  • METHODS: We retrospectively analyzed the clinical appearance and pathological findings in five patients with CMVPTC and sequenced exon 3 of CTNNB1 and exon 15 of BRAF in tumor tissue.
  • Immunohistochemically, most tumor cells showed nuclear expression of thyroid transcription factor-1, estrogen and progesterone receptors, and p53; cytoplasmic expression of cytokeratins 7 and 19, vimentin, and bcl-2; and cytoplasmic and nuclear accumulation of beta-catenin and galectin-3.
  • There was no expression of thyroglobulin, cytokeratin 5/6, or human mesothelial cell-1.
  • [MeSH-major] Adenocarcinoma, Papillary / genetics. Proto-Oncogene Proteins B-raf / genetics. Thyroid Neoplasms / genetics. beta Catenin / genetics

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19534622.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / beta Catenin; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


16. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A: 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int; 2010 May;60(5):395-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies showed that this alteration might be useful for differentiating benign from malignant mesothelial tumors in cytology and surgical specimens.
  • The purpose of this study is to evaluate the diagnostic utility of 9p21 homozygous deletion assessed by FISH in mesothelial neoplasm and hyperplasia of Japanese patients using paraffin-embedded tissue.
  • In contrast, no cases of adenomatoid tumor, benign mesothelial multicystic tumor, reactive mesothelial hyperplasia or pleuritis showed 9p21 deletion (P < 0.005).
  • 9p21 homozygous deletion correlated well with p16 protein expression in the tumor cells.
  • Our study suggests that 9p21 homozygous deletion assessed by FISH on paraffin-embedded tissue may be very useful for differentiating MM from reactive mesothelial proliferation.
  • [MeSH-major] Chromosomes, Human, Pair 9. Genes, p16. Heart Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. Epithelium / pathology. Female. Gene Deletion. Gene Dosage. Humans. Pericardium / metabolism. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518890.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


17. Yeh CJ, Chuang WY, Chou HH, Jung SM, Hsueh S: Multiple extragenital adenomatoid tumors in the mesocolon and omentum. APMIS; 2008 Nov;116(11):1016-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adenomatoid tumors are benign mesothelial neoplasms most commonly found in the male and female genital tracts.
  • The patient was transferred to our hospital without resection due to the intraoperative finding of multiple peritoneal tumors.
  • At our hospital, an 8.0x7.5x6.0 cm tumor at the mesocolon of the sigmoid colon and three omental nodules measuring up to 2.5x2.0x1.7 cm were resected.
  • Immunohistochemically, the tumor cells were positive for pan-cytokeratin AE1/AE3, vimentin, cytokeratin 5/6 and calretinin.
  • [MeSH-major] Adenomatoid Tumor / pathology. Mesocolon / pathology. Neoplasms, Multiple Primary / pathology. Omentum / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133002.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


18. Jayne D: Molecular biology of peritoneal carcinomatosis. Cancer Treat Res; 2007;134:21-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Initial tumour-mesothelial interaction appears to involve several adhesion molecules, including CD44, the Selectins, and various leukocyte associated antigens.
  • The exact molecules involved are probably determined by the nature of the metastatic tumour cell.
  • Invasion of the mesothelial monolayer appears to occur by tumour-induced mesothelial apoptosis, at least in part via the Fas/FasL system, although invasion between intercellular spaces may also play a role.
  • Adhesion to the submesothelial connective tissue is mediated by tumour integrin binding.
  • The peritoneal stromal tissue appears to be a favourable host for tumour proliferation, providing a rich source of growth factors and chemokines known to be involved in tumour metastasis.
  • Angiogenesis is vital to peritoneal tumour growth and although the peritoneum has a well developed blood supply the angiogenic events specific to peritoneal tumour metastasis remain to be elucidated.
  • Further investigation is required to unravel the complexities of the peritoneal metastatic cascade and this will inevitably open up many avenues for novel therapeutic manipulation and disease modulation.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma / secondary. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Cell Adhesion. Cell Proliferation. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Neoplasm Invasiveness. Neovascularization, Pathologic / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17633045.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


19. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


20. Salviato T, Altavilla G, Busatto G, Pizzolitto S, Falconieri G: Diffuse intra-abdominal clear cell myomelanocytic tumor: report of an unusual presentation of "PEComatosis" simulating peritoneal mesothelioma. Ann Diagn Pathol; 2006 Dec;10(6):352-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse intra-abdominal clear cell myomelanocytic tumor: report of an unusual presentation of "PEComatosis" simulating peritoneal mesothelioma.
  • We report a case of diffuse myomelanocytic tumor of the peritoneum that simulates, clinically and instrumentally, a malignant mesothelioma.
  • Scattered tumor masses were present as well.
  • Histological examination revealed a tumor composed of epithelioid and spindle cells, exhibiting either a clear or slightly eosinophilic cytoplasm and a mild to moderate nuclear pleomorphism.
  • Immunohistochemically, tumor cells were positive for HMB45, melan-A, and smooth muscle actin, but negative for other antibodies, including epithelial markers, desmin, and S100 protein.
  • We believe that this case represents an example of myomelanocytic tumor of uncertain biologic potential, a member of the recently devised perivascular epithelioid cell tumors (PEComa), with an unusual presentation simulating a diffuse mesothelial neoplasm.
  • [MeSH-major] Abdominal Neoplasms / pathology. Epithelioid Cells / pathology. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Smooth Muscle Tumor / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm. Biomarkers, Tumor / analysis. Cell Proliferation. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Leiomyoma, Epithelioid. Melanoma-Specific Antigens. Neoplasm Proteins / analysis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126254.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


21. Tafazzoli A, Raza A, Martin SE: Primary diagnosis of malignant mesothelioma by fine-needle aspiration of a supraclavicular lymph node. Diagn Cytopathol; 2005 Aug;33(2):122-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant mesothelioma is a rare neoplasm with poor prognosis.
  • The pleural form is defined as a malignant tumor of mesothelial cells with a diffuse growth pattern involving the visceral and parietal surfaces of the pleura.
  • The mesothelial origin of the tumor was confirmed with immunohistochemical studies.
  • [MeSH-major] Lymph Nodes / pathology. Mesothelioma / pathology. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16007670.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Hsu IL, Su WC, Yan JJ, Chang JM, Lai WW: Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer; 2009 Sep;65(3):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical staining of pleural samples showed that VEGF was secreted by both mesothelial and tumor cells.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Non-Small-Cell Lung / blood supply. Epithelium / metabolism. Lung Neoplasms / blood supply. Neovascularization, Pathologic. Vascular Endothelial Growth Factor A / secretion
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Disease Progression. Erythrocytes. Fibroblast Growth Factor 2 / metabolism. Humans. Interleukin-8 / secretion. Middle Aged. Prognosis. Smoking. Survival Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19157636.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-8; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


24. Choi JH, Park JT, Davidson B, Morin PJ, Shih IeM, Wang TL: Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res; 2008 Jul 15;68(14):5716-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion.
  • In this report, we identify Jagged-1 as the highest expressed Notch ligand in ovarian tumor cells as well as in peritoneal mesothelial cells that are in direct contact with disseminated ovarian cancer cells.
  • Cell-cell adhesion and cellular proliferation were reduced in Notch3-expressing ovarian cancer cells that were cocultured with Jagged-1 knockdown mesothelial and tumor feeder cells.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1993 Sep 15;85(18):1513-9 [8360934.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):48-54 [15108805.001]
  • [Cites] EMBO J. 1999 Apr 15;18(8):2196-207 [10205173.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2353-63 [15781650.001]
  • [Cites] Dev Neurosci. 2006;28(1-2):58-69 [16508304.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6312-8 [16778208.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Lancet Oncol. 2006 Nov;7(11):925-34 [17081918.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):1879-82 [17332312.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2613-7 [17351921.001]
  • [Cites] Mol Cell Biol. 2000 Sep;20(18):6913-22 [10958687.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):10-7 [11277643.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8771-9 [12496248.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13607-10 [12591935.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4144-9 [12874019.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34427-37 [12826675.001]
  • [Cites] Cell. 1995 Mar 24;80(6):909-17 [7697721.001]
  • (PMID = 18632624.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA129080-01A1; United States / NCI NIH HHS / CA / CA103937-04; United States / NCI NIH HHS / CA / R01 CA103937-05; United States / NCI NIH HHS / CA / CA103937-05; United States / NCI NIH HHS / CA / CA129080-01A1; United States / NCI NIH HHS / CA / R01 CA103937-04; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / R01 CA103937
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Enzyme Inhibitors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ligands; 0 / Membrane Proteins; 0 / NOTCH3 protein, human; 0 / Receptors, Notch; 134324-36-0 / Serrate proteins
  • [Other-IDs] NLM/ NIHMS54634; NLM/ PMC2562671
  •  go-up   go-down


25. Alkhamesi NA, Ziprin P, Pfistermuller K, Peck DH, Darzi AW: ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis; 2005;22(6):449-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary interaction between tumour cells and the mesothelium is a vital step in initiating this process.
  • Our aim was to determine the role of the intercellular adhesion molecule-1 (ICAM-1) in mesothelial-tumour adhesion and the effectiveness of therapeutic intervention.
  • Mesothelial cells were derived from omental tissue.
  • Functional effects on tumour adhesion to a mesothelial monolayer were determined via a Calcein-AM in vitro adhesion assay.
  • In vivo studies were performed utilising 30 WAG/rij rats, which underwent mini-laparotomy with the injection of 1 x 10(5 )CC 513 tumour cells intraperitoneally.
  • Tumour growth was assessed macroscopically and microscopically by two independent examiners.
  • Mesothelial cells expressed high level of ICAM-1, which was up-regulated by the presence of TNF-alpha.
  • A significant decrease in tumour-mesothelial cell adhesion in vitro and complete aberration of tumour growth in vivo was observed with heparin application.
  • [MeSH-major] Carcinoma / drug therapy. Cell Adhesion / drug effects. Heparin / therapeutic use. Intercellular Adhesion Molecule-1 / metabolism. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Down-Regulation. Epithelium / drug effects. Epithelium / metabolism. Epithelium / pathology. Flow Cytometry. Humans. Hyaluronic Acid / pharmacology. Hyaluronic Acid / therapeutic use. Rats. Tumor Necrosis Factor-alpha / pharmacology

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • Hazardous Substances Data Bank. HEPARIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320108.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 126547-89-5 / Intercellular Adhesion Molecule-1; 9004-61-9 / Hyaluronic Acid; 9005-49-6 / Heparin
  •  go-up   go-down


26. Heyman L, Kellouche S, Fernandes J, Dutoit S, Poulain L, Carreiras F: Vitronectin and its receptors partly mediate adhesion of ovarian cancer cells to peritoneal mesothelium in vitro. Tumour Biol; 2008;29(4):231-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial ovarian cancer cells metastasize by implanting onto the peritoneal mesothelial surface of the abdominal cavity.
  • The aim of our study was to focus on the role of vitronectin (Vn) and its receptors, alpha(v) integrins and urokinase plasminogen activator receptor (uPAR), in the interactions of ovarian adenocarcinoma cells (IGROV1 and SKOV3 cell lines) with mesothelial cells (MeT-5A cell line and primary cultures).
  • We developed two distinct methods for the evaluation of in vitro cell-cell adhesion using cocultures of the tumor and mesothelial cells.
  • Both adhesion assays revealed a strong ability of ovarian cancer cells to adhere preferentially to mesothelial intercellular junctions.
  • Adhesion of ovarian carcinoma cells to mesothelial cells was significantly inhibited using anti-Vn-, -alpha(v)-integrin- and -uPAR-blocking antibodies or cyclic peptide cRGDfV.
  • [MeSH-major] Integrin alphaVbeta3 / physiology. Ovarian Neoplasms / pathology. Peritoneum / cytology. Vitronectin / physiology
  • [MeSH-minor] Cell Adhesion. Cell Line, Tumor. Epithelial Cells / cytology. Female. Humans. Integrin alphaV / analysis. Integrin alphaV / physiology. Receptors, Cell Surface / analysis. Receptors, Cell Surface / physiology. Receptors, Urokinase Plasminogen Activator

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18781095.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Integrin alphaV; 0 / Integrin alphaVbeta3; 0 / PLAUR protein, human; 0 / Receptors, Cell Surface; 0 / Receptors, Urokinase Plasminogen Activator; 0 / Vitronectin
  •  go-up   go-down


27. Alkhamesi NA, Roberts G, Ziprin P, Peck DH: Induction of Proteases in Peritoneal Carcinomatosis, the Role of ICAM-1/CD43 Interaction. Biomark Insights; 2007 Oct 08;2:377-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that ICAM-1-CD43 interaction plays a significant role in tumor adhesion.
  • However, an invasive phenotype is critical to establish tumor progression via cell associated and secreted proteases including matrix metalloproteinases.
  • We investigated the role of direct and indirect signaling between the mesothelium and the tumor cells in enhancing tumor invasion and possible therapeutic intervention.
  • METHODS: Mesothelial cells were enzymatically derived from human omental tissue and implanted in 24 wells plates.
  • Colorectal cancer cells were then introduced and allowed a direct and an indirect contact with the mesothelial layer.
  • RESULTS: MMP production was observed in mesothelial and tumor cells.
  • CONCLUSIONS: ICAM-1-CD43 interaction plays a vital role in tumor cells-peritoneum adhesion and invasion, which is manifested by the increased production of MMPs leading to tumor invasion and peritoneal loco-regional.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1999 Jan 30;353(9150):391-9 [9950460.001]
  • [Cites] Dis Colon Rectum. 2000 Oct;43(10):1341-6; discussion 1347-8 [11052509.001]
  • [Cites] Cell Adhes Commun. 1997 Mar;4(6):439-55 [9177905.001]
  • [Cites] World J Surg. 1996 Jun;20(5):585-91; discussion 592 [8661635.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2749-54 [8610113.001]
  • [Cites] J Cell Physiol. 1993 Aug;156(2):235-46 [8344982.001]
  • [Cites] J Natl Cancer Inst. 1991 Jun 5;83(11):775-9 [1645772.001]
  • [Cites] Dis Colon Rectum. 1991 Aug;34(8):723-7 [1855433.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Apr;11(4):731-41 [3980270.001]
  • [Cites] Kidney Int. 1990 Jun;37(6):1563-70 [2362409.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Biol Chem. 2004 Aug;385(8):755-61 [15449712.001]
  • [Cites] Cancer Control. 2003 May-Jun;10(3):224-38 [12794621.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Surgery. 2007 Jun;141(6):705-7 [17560245.001]
  • [Cites] J Control Release. 2007 May 14;119(1):121-7 [17382424.001]
  • [Cites] J Surg Oncol. 2007 Feb 1;95(2):93-6 [17262739.001]
  • [Cites] Br J Oral Maxillofac Surg. 2006 Dec;44(6):482-6 [16338034.001]
  • [Cites] Clin Exp Metastasis. 2005;22(6):449-59 [16320108.001]
  • [Cites] Surg Endosc. 2005 Aug;19(8):1142-6 [16021376.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1802-10 [16051479.001]
  • [Cites] J Immunol. 1998 Mar 15;160(6):2967-73 [9510201.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Oncol Rep. 2002 May-Jun;9(3):511-4 [11956618.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Mar;282(3):H983-9 [11834496.001]
  • [Cites] J Surg Res. 2002 Feb;102(2):57-62 [11795999.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):71-8 [9096668.001]
  • (PMID = 19662219.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717821
  • [Keywords] NOTNLM ; CD43 / Colorectal cancer / Heparin / ICAM-1 / MMP-2 and MMP-9 / Mesothelial cells
  •  go-up   go-down






Advertisement